• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多民族甲状腺相关眼病患者发生甲状腺功能障碍性视神经病变的预测性人口统计学和临床特征:一项回顾性队列研究

Predictive demographic and clinical features for the development of dysthyroid optic neuropathy in a multi-ethnic TED population: a retrospective cohort study.

作者信息

Moledina Malik, Lee Vickie, Alnahrawy Ahmed, Fydanaki Ourania, George Nicole, Hubby Nour, Metcalf Daisy, Man Natalie, Guevara Gabriella, Feeney Claire, Akshikar Rashmi, Jain Rajni, Aziz Ahmad, Bravis Vassiliki, Meeran Karim

机构信息

Oculoplastics and Adnexal Service, Western Eye Hospital, Imperial College NHS Foundation Trust, 53-173 Marylebone Rd, London, NW1 5QH, UK.

Imperial College Ophthalmology Research Group (ICORG), London, UK.

出版信息

Thyroid Res. 2025 Jul 22;18(1):37. doi: 10.1186/s13044-025-00249-4.

DOI:10.1186/s13044-025-00249-4
PMID:40691639
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12281705/
Abstract

BACKGROUND

Dysthyroid Optic Neuropathy (DON) is a sight-threatening complication of Thyroid Eye Disease (TED). This study aims to identify the risk and predictive factors for DON in a multi-ethnic TED cohort.

METHODS

Retrospective, cohort study of consecutive TED patients attending a multidisciplinary service over an 11-year period. Consecutive patients aged over 18 years old with a minimum of 6 months follow-up post-diagnosis of TED were included. We compared those patients with DON and those without (no-DON) to determine which factors were more prevalent in patients with DON.

RESULTS

There were 26 and 516 consecutive patients with DON and no-DON. The DON prevalence in the cohort was 5.0%. The DON group had a Mean Age at TED Diagnosis (MATD) of 57.8 vs. 46.1 years in the no-DON group. The mean presenting CAS, TRAb and Gorman Diplopia Score (GDS) were significantly higher 3.73 ± 1.80, 2.76 ± 1.05 and 11.31 ± 11.90 vs. 0.54 ± 0.80, 0.48 ± 0.90 and 6.95 ± 9.22 in the DON compared to the no-DON group respectively (p = 0.00, p = 0.00 and p = 0.04). On multivariable regression, we found the following risk factors for developing DON (Odds Ratios): MATD ≥ 53 years (5.2 p = 0.00), presenting CAS ≥ 4 (P = 0.00), presenting GDS ≥ 3 (7.5 p = 0.00), diabetes (5.7 p = 0.00), and baseline TRAb ≥ 5.0 IU/L (2.9 p = 0.04).

CONCLUSION

Patients with diabetes, increased MATD, and high presenting CAS, GDS, and TRAb are at increased risk of developing DON in our cohort. Clinicians should be especially vigilant of the risk of sight-threatening complications in TED patients with more than one of the above risk factors.

摘要

背景

甲状腺功能异常性视神经病变(DON)是甲状腺眼病(TED)的一种威胁视力的并发症。本研究旨在确定多民族TED队列中DON的风险和预测因素。

方法

对在11年期间接受多学科服务的连续TED患者进行回顾性队列研究。纳入年龄在18岁以上、确诊TED后至少随访6个月的连续患者。我们比较了患有DON的患者和未患有DON的患者(非DON),以确定哪些因素在患有DON的患者中更普遍。

结果

分别有26例和516例连续的DON患者和非DON患者。队列中DON的患病率为5.0%。DON组的TED诊断时平均年龄(MATD)为57.8岁,而非DON组为46.1岁。与非DON组相比,DON组的初始临床活动评分(CAS)、促甲状腺素受体抗体(TRAb)和戈尔曼复视评分(GDS)的平均值显著更高,分别为3.73±1.80、2.76±1.05和11.31±11.90,而非DON组分别为0.54±0.80、0.48±0.90和6.95±9.22(p = 0.00、p = 0.00和p = 0.04)。在多变量回归分析中,我们发现以下发生DON的风险因素(比值比):MATD≥53岁(5.2,p = 0.00)、初始CAS≥4(P = 0.00)、初始GDS≥3(7.5,p = 0.00)、糖尿病(5.7,p = 0.00)以及基线TRAb≥5.0 IU/L(2.9,p = 0.04)。

结论

在我们的队列中,患有糖尿病、MATD增加以及初始CAS、GDS和TRAb较高的患者发生DON的风险增加。临床医生应特别警惕具有上述多种风险因素的TED患者发生威胁视力并发症的风险。

相似文献

1
Predictive demographic and clinical features for the development of dysthyroid optic neuropathy in a multi-ethnic TED population: a retrospective cohort study.多民族甲状腺相关眼病患者发生甲状腺功能障碍性视神经病变的预测性人口统计学和临床特征:一项回顾性队列研究
Thyroid Res. 2025 Jul 22;18(1):37. doi: 10.1186/s13044-025-00249-4.
2
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
3
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
4
Clinical Features of Chinese Patients with Thyroid Eye Disease: A Multicenter Retrospective Study.中国甲状腺眼病患者的临床特征:一项多中心回顾性研究。
Thyroid. 2025 Aug 11. doi: 10.1177/10507256251359559.
5
Surgical orbital decompression for thyroid eye disease.甲状腺眼病的眼眶减压手术
Cochrane Database Syst Rev. 2011 Dec 7(12):CD007630. doi: 10.1002/14651858.CD007630.pub2.
6
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
7
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
8
Does Augmenting Irradiated Autografts With Free Vascularized Fibula Graft in Patients With Bone Loss From a Malignant Tumor Achieve Union, Function, and Complication Rate Comparably to Patients Without Bone Loss and Augmentation When Reconstructing Intercalary Resections in the Lower Extremity?对于因恶性肿瘤导致骨缺损的患者,在重建下肢节段性切除时,采用带血管游离腓骨移植来增强照射后的自体骨移植,其骨愈合、功能及并发症发生率与无骨缺损且未进行增强的患者相比是否相当?
Clin Orthop Relat Res. 2025 Jun 26. doi: 10.1097/CORR.0000000000003599.
9
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
10
Laser therapy for retinopathy in sickle cell disease.激光疗法治疗镰状细胞病视网膜病变。
Cochrane Database Syst Rev. 2022 Dec 12;12(12):CD010790. doi: 10.1002/14651858.CD010790.pub3.

本文引用的文献

1
Radiological Activity Score (RAS)-MRI Characteristics in Dysthyroid Optic Neuropathy in a Multi-Ethnic Thyroid Eye Disease Population.多民族甲状腺眼病患者甲状腺功能异常性视神经病变的放射学活动评分(RAS)-MRI特征
Clin Endocrinol (Oxf). 2025 Sep;103(3):385-395. doi: 10.1111/cen.15272. Epub 2025 May 20.
2
The changing landscape of thyroid eye disease: current clinical advances and future outlook.甲状腺眼病的变化格局:当前临床进展及未来展望。
Eye (Lond). 2024 Jun;38(8):1425-1437. doi: 10.1038/s41433-024-02967-9. Epub 2024 Feb 19.
3
How Age Affects Graves' Orbitopathy-A Tertiary Center Study.
年龄如何影响格雷夫斯眼眶病——一项三级中心研究
J Clin Med. 2024 Jan 4;13(1):290. doi: 10.3390/jcm13010290.
4
Extraocular muscle enlargement in dysthyroid optic neuropathy.甲状腺相关眼病性视神经病变中的眼外肌肿大。
Can J Ophthalmol. 2024 Oct;59(5):e542-e546. doi: 10.1016/j.jcjo.2023.11.015. Epub 2023 Dec 16.
5
Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.特罗特单抗治疗长病程和低疾病活动度甲状腺眼病患者的疗效和安全性。
J Clin Endocrinol Metab. 2023 Dec 21;109(1):25-35. doi: 10.1210/clinem/dgad637.
6
Predictive factors of development of dysthyroid optic neuropathy among individuals with thyroid-eye disease.甲状腺眼病患者中伴发甲状腺相关眼病性视神经病变的预测因素。
Eur J Ophthalmol. 2024 May;34(3):834-842. doi: 10.1177/11206721231199868. Epub 2023 Sep 3.
7
Thyrotropin Receptor Autoantibody Assessment in Thyroid Eye Disease: Does the Assay Type Matter?促甲状腺激素受体自身抗体在甲状腺眼病中的评估:检测方法重要吗?
Korean J Ophthalmol. 2023 Apr;37(2):147-156. doi: 10.3341/kjo.2022.0131. Epub 2023 Apr 5.
8
Dysthyroid optic neuropathy: Demographics, risk factors, investigations, and management outcomes.甲状腺功能异常性视神经病变:人口统计学、危险因素、检查及治疗结果。
Indian J Ophthalmol. 2022 Dec;70(12):4419-4426. doi: 10.4103/ijo.IJO_719_22.
9
Inflammasome activation as a link between obesity and thyroid disorders: Implications for an integrated clinical management.作为肥胖症与甲状腺疾病之间关联的纽带,炎症小体的激活:对综合临床管理的启示。
Front Endocrinol (Lausanne). 2022 Aug 19;13:959276. doi: 10.3389/fendo.2022.959276. eCollection 2022.
10
Thyroid disease-specific quality of life questionnaires - A systematic review.甲状腺疾病特异性生活质量调查问卷 - 系统评价。
Endocrinol Diabetes Metab. 2022 Sep;5(5):e357. doi: 10.1002/edm2.357. Epub 2022 Jul 20.